Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Accumulated Depreciation & Amortization Accumulated Depreciation & Amortization EBIAT Machine, Furnitures, Fixtures & Other Other Gross PP&E Adjustments Other Gross PP&E Adjustments Property, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In Process Shares Issued Shares Outstanding Shares Outstanding

Ratios

Oric Pharmaceuticals (ORIC) Preferred Shares Issued (2019)

Oric Pharmaceuticals filings provide 1 years of Preferred Shares Issued readings, the most recent being -$135000.0 for Q4 2019.

Quarterly Preferred Shares Issued changed N/A to -$135000.0 in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $55.5 million through Dec 2021, changed N/A year-over-year, with the annual reading at $70.8 million for FY2019, 86.64% up from the prior year.
Preferred Shares Issued hit -$135000.0 in Q4 2019 for Oric Pharmaceuticals, down from $5.8 million in the prior quarter.
Across five years, Preferred Shares Issued topped out at $49.9 million in Q2 2019 and bottomed at -$135000.0 in Q4 2019.